- 2023-2024 EMBRACE MBC Virtual Forum Series
- ASCO® GU 2024
- ASCO® 2023
- COVID-19
- Leukemia
- Lymphoma
- Myeloma
- MDS and MPN
- Breast
- Lung
- Gynecologic
- Genitourinary
- Gastrointestinal
- Colorectal
- Basic Science
- Supportive and Palliative Care
- CNS
- Skin
- Head and Neck
- Business
Playback speed
10 seconds
SABCS 2022 Phase 3 TROPiCS-02 Study: Exposure-Adjusted Incidence Rates of Adverse Events of Sacituzumab Govitecan vs. Treatment of Physician’s Choice in HR+/HER2- mBC
By
SABCS 2022 Conference Coverage
FEATURING
Sara Tolaney
By
SABCS 2022 Conference Coverage
FEATURING
Sara Tolaney
64 views
December 19, 2022
Login to view comments.
Click here to Login
Breast